{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:04:09Z","timestamp":1790179449163,"version":"4.1.0"},"reference-count":21,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"abstract":"\n Importance<\/jats:title>\n Lichen planus is a chronic, highly pruritic, inflammatory disease that affects the skin and other tissues.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the efficacy and safety of ruxolitinib, 1.5%, cream in patients with cutaneous lichen planus.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This phase 2, 16-week, randomized, double-blind, vehicle-controlled trial with a 16-week open-label extension was conducted from November 2022 to February 2024. Patients were enrolled from 19 sites in the US and Canada. The trial included adults with predominantly cutaneous lichen planus, an Investigator\u2019s Global Assessment (IGA) score of 3 or 4, an Itch Numerical Rating Scale score of 4 or greater, and an affected body surface area of 20% or less were enrolled. Data were analyzed from February to August 2024.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Patients were randomized 1:1 to ruxolitinib, 1.5%, twice daily cream or vehicle cream for 16 weeks, after which eligible patients applied ruxolitinib cream twice daily as needed in a 16-week, open-label extension.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was IGA treatment success (IGA score of 0 or 1 [clear\/almost clear skin] with a \u22652-grade improvement from baseline) at week 16.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 64 randomized patients, 46 (72%) were female, 18 (28%) were male, 18 (28%) were African American\/Black, 4 (6%) were Asian, 40 (63%) were White, and the median (range) age was 57.0 (18-78) years. Significantly more patients who applied ruxolitinib, 1.5%, cream vs vehicle achieved IGA treatment success (50.0% [95% CI, 31.9%-68.1%] vs 21.9% [95% CI, 9.3%-40.0%], respectively; response rate difference, 29.4% [95% CI, 7.6%-51.3%];\n P<\/jats:italic>\n \u2009=\u2009.01; primary end point) at week 16, with further improvement to week 32. Similar results were observed in the proportion of patients who achieved a 4 or greater\u2013point improvement from baseline in Itch Numerical Rating Scale score (week 16, 48.4% [95% CI, 30.2%-66.9%] vs 16.1% [95% CI, 5.5%-33.7%]; response rate difference, 33.5%; 95% CI, 12.2%-54.9%;\n P<\/jats:italic>\n \u2009=\u2009.004; secondary end point). No serious treatment-emergent adverse events or discontinuations due to an adverse event were observed with ruxolitinib cream.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The results of this randomized clinical trial suggest that ruxolitinib cream significantly reduced lesions and itch in patients with lichen planus. Therefore, ruxolitinib cream represents a potential treatment option for patients with cutaneous lichen planus.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT05593432<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2026.3646","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:30:40Z","timestamp":1790177440000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus"],"prefix":"10.1001","author":[{"given":"Aaron R.","family":"Mangold","sequence":"first","affiliation":[{"name":"Mayo Clinic, Scottsdale, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lockshin","sequence":"additional","affiliation":[{"name":"US Dermatology Partners, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Lai","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Rong","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haq","family":"Nawaz","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Ehst","sequence":"additional","affiliation":[{"name":"Oregon Medical Research Center, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"doi260043r2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.737813","article-title":"Lichen planus.","volume":"8","author":"Boch","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"doi260043r3","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s13555-023-00968-2","article-title":"Patient experience of lichen planus: a qualitative exploration of signs, symptoms, and health-related quality of life impacts.","volume":"13","author":"Mahon-Smith","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"doi260043r4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2005.01.010","article-title":"Adverse effects of topical glucocorticosteroids.","volume":"54","author":"Hengge","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi260043r5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40257-015-0160-6","article-title":"Treatments for cutaneous lichen planus: a systematic review and meta-analysis.","volume":"17","author":"Atzmony","year":"2016","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"doi260043r6","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jaad.2019.04.027","article-title":"Clinical epidemiology and treatment of lichen planus: a retrospective review of 2 tertiary care centers.","volume":"81","author":"Schwager","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi260043r7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179436","article-title":"Rapid response of lichen planus to baricitinib associated with suppression of cytotoxic CXCL13+CD8+ T cells.","volume":"135","author":"Hwang","year":"2024","journal-title":"J Clin Invest"},{"issue":"2","key":"doi260043r8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/exd.14226","article-title":"The inflammation in cutaneous lichen planus is dominated by IFN-? and IL-21-a basis for therapeutic JAK1 inhibition.","volume":"30","author":"Pietschke","year":"2021","journal-title":"Exp Dermatol"},{"issue":"511","key":"doi260043r9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav7561","article-title":"IFN-? enhances cell-mediated cytotoxicity against keratinocytes via JAK2\/STAT1 in lichen planus.","volume":"11","author":"Shao","year":"2019","journal-title":"Sci Transl Med"},{"issue":"8","key":"doi260043r11","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jid.2022.01.015","article-title":"Ruxolitinib cream in the treatment of cutaneous lichen planus: a prospective, open-label study.","volume":"142","author":"Brumfiel","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"22","key":"doi260043r12","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2025.4347","article-title":"CONSORT 2025 statement: updated guideline for reporting randomized trials.","volume":"333","author":"Hopewell","year":"2025","journal-title":"JAMA"},{"issue":"4","key":"doi260043r13","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies.","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi260043r14","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","article-title":"Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies.","volume":"88","author":"Papp","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"16","key":"doi260043r15","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo.","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"doi260043r16","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/bjd\/ljae181","article-title":"Secukinumab in adult patients with lichen planus: efficacy and safety results from the randomized placebo-controlled proof-of-concept PRELUDE study.","volume":"191","author":"Passeron","year":"2024","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi260043r17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jaad.2024.09.032","article-title":"Topical ruxolitinib in the management of frontal fibrosing alopecia and\/or lichen planopilaris: a single-center retrospective cohort study.","volume":"92","author":"Williams","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi260043r19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jaad.2024.09.073","article-title":"A phase 2a trial of brepocitinib for cicatricial alopecia.","volume":"92","author":"David","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi260043r21","first-page":"53","article-title":"Diagnosis and treatment of lichen planus.","volume":"84","author":"Usatine","year":"2011","journal-title":"Am Fam Physician"},{"key":"doi260043r1","volume-title":"Fitzpatrick\u2019s Dermatology","author":"Mangold","year":"2019","edition":"9th ed"},{"key":"doi260043r20","author":"Mangold"},{"key":"doi260043r10","unstructured":"Incyte Corporation. Opzelura. Accessed December 31, 2025. https:\/\/www.opzelura.com\/prescribing-information.pdf"},{"key":"doi260043r18","doi-asserted-by":"crossref","unstructured":"Stockard? A, Leibovit-Reiben? Z, Hu? B, . TYK2 inhibition with deucravacitinib improves clinical outcomes and resolves interferon-driven inflammation in lichen planopilaris.? medRxiv. 2026. doi:10.64898\/2026.03.13.26348272","DOI":"10.64898\/2026.03.13.26348272"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2853980\/jamadermatology_mangold_2026_oi_260043_1788536296.58027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:30:42Z","timestamp":1790177442000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2853980"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":21,"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.3646","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}